Feasibility of psilocybin-based therapy in veterans with PTSD

Researchers examined the safety and efficacy of psilocybin-assisted therapy in high-risk patients with posttraumatic stress disorder.

In an open-label pilot trial published in Communications Medicine, the researchers assigned 12 veterans aged 21 to 64 years with treatment-resistant PTSD to receive psilocybin-assisted therapy consisting of eight hours of therapy, two psilocybin dosing sessions and an additional eight hours of post-psilocybin therapy. They noted that veterans often experience greater PTSD severity.

The researchers found that PTSD symptoms significantly decreased up to one month of follow-up, and about 75% of the participants had PTSD remission. The patients experienced no increases in suicidal ideation or behavior. There were no serious adverse events observed during the study, and the participants’ heart rates remained within a safe range while receiving psilocybin.

The findings suggested that psilocybin-assisted therapy may be safe and feasible in this patient population. The preliminary results demonstrated clinical improvement in PTSD symptoms and severity.

Read more: Communications Medicine

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.